Damien Salauze, PharmD, started his career as Clinical Pathologist at the university hospital of Rouen. He then joined Institut Pasteur in Paris where he defended a PhD in biotechnology in the lab of Julian Davies as a Rhône-Poulenc fellow. He was hired by Rhône-Poulenc in 1990 and became head of a unit within the toxicology department, with responsibilities for the development of antibiotics (including Synercid ®). After having completed an MBA at INSEAD in 1994, he became sales representative (Lovenox®), then product manager (responsible for the launch of Taxotere®), then international marketing director for oncology at Rhône-Poulenc Rorer which later became Aventis. In 2002, he entered the Venture-Capital business as partner at Auriga Partners. Few years later he was appointed CEO of Novagali Pharma (which was later listed in Paris), then CEO of Sepal Pharma (for which he conducted a Public Offering Subscription in London). He joined Institut Curie in 2008 as Tech Transfer Officer. He now heads FINDMED, which is a consortium of 10 Carnot institutes dedicated to R&D collaborations with French SMEs involved in drug-development, and holds a position of entrepreneur in residence at Spine and Brain Institute, Paris. Damien Salauze teaches on drug-development strategy at the Faculty of Pharmacy of Rouen, seats at the board of several biotech companies in France, and is a full-member of the National Academy of Pharmacy.